Wolfe Research Initiates Coverage On Zymeworks with Outperform Rating, Announces $61 Price Target

Wolfe Research initiates coverage on Zymeworks (NYSE:ZYME) with a Outperform rating and a $61 price target.

Benzinga · 01/10/2020 16:36

Wolfe Research initiates coverage on Zymeworks (NYSE:ZYME) with a Outperform rating and a $61 price target.